vs
Loar Holdings Inc.（LOAR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Loar Holdings Inc.的季度营收约是再鼎医药的1.0倍（$131.8M vs $127.1M），Loar Holdings Inc.同比增速更快（19.3% vs 17.1%），过去两年再鼎医药的营收复合增速更高（20.8% vs 19.8%）
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
LOAR vs ZLAB — 直观对比
营收规模更大
LOAR
是对方的1.0倍
$127.1M
营收增速更快
LOAR
高出2.2%
17.1%
两年增速更快
ZLAB
近两年复合增速
19.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $131.8M | $127.1M |
| 净利润 | $12.5M | — |
| 毛利率 | 52.1% | 51.0% |
| 营业利润率 | 18.0% | -54.6% |
| 净利率 | 9.5% | — |
| 营收同比 | 19.3% | 17.1% |
| 净利润同比 | 239.5% | — |
| 每股收益（稀释后） | $0.13 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LOARZLAB
| Q4 25 | $131.8M | $127.1M | ||
| Q3 25 | $126.8M | $115.4M | ||
| Q2 25 | $123.1M | $109.1M | ||
| Q1 25 | $114.7M | $105.7M | ||
| Q4 24 | $110.4M | $108.5M | ||
| Q3 24 | $103.5M | $101.8M | ||
| Q2 24 | $97.0M | $100.1M | ||
| Q1 24 | $91.8M | $87.1M |
净利润LOARZLAB
| Q4 25 | $12.5M | — | ||
| Q3 25 | $27.6M | $-36.0M | ||
| Q2 25 | $16.7M | $-40.7M | ||
| Q1 25 | $15.3M | $-48.4M | ||
| Q4 24 | $3.7M | — | ||
| Q3 24 | $8.7M | $-41.7M | ||
| Q2 24 | $7.6M | $-80.3M | ||
| Q1 24 | $2.2M | $-53.5M |
毛利率LOARZLAB
| Q4 25 | 52.1% | 51.0% | ||
| Q3 25 | 52.7% | 59.5% | ||
| Q2 25 | 53.8% | 60.6% | ||
| Q1 25 | 52.1% | 63.6% | ||
| Q4 24 | 48.9% | 61.5% | ||
| Q3 24 | 51.1% | 64.1% | ||
| Q2 24 | 49.0% | 64.9% | ||
| Q1 24 | 48.4% | 61.4% |
营业利润率LOARZLAB
| Q4 25 | 18.0% | -54.6% | ||
| Q3 25 | 22.9% | -42.3% | ||
| Q2 25 | 22.2% | -50.3% | ||
| Q1 25 | 22.8% | -53.3% | ||
| Q4 24 | 19.2% | -62.6% | ||
| Q3 24 | 22.1% | -66.6% | ||
| Q2 24 | 22.9% | -76.0% | ||
| Q1 24 | 23.3% | -80.7% |
净利率LOARZLAB
| Q4 25 | 9.5% | — | ||
| Q3 25 | 21.8% | -31.2% | ||
| Q2 25 | 13.6% | -37.3% | ||
| Q1 25 | 13.4% | -45.8% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 8.4% | -40.9% | ||
| Q2 24 | 7.9% | -80.2% | ||
| Q1 24 | 2.4% | -61.4% |
每股收益（稀释后）LOARZLAB
| Q4 25 | $0.13 | $-0.05 | ||
| Q3 25 | $0.29 | $-0.03 | ||
| Q2 25 | $0.17 | $-0.04 | ||
| Q1 25 | $0.16 | $-0.04 | ||
| Q4 24 | $-11023.48 | $-0.09 | ||
| Q3 24 | $0.09 | $-0.04 | ||
| Q2 24 | $0.09 | $-0.08 | ||
| Q1 24 | $11023.54 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.8M | $689.6M |
| 总债务越低越好 | $715.7M | — |
| 股东权益账面价值 | $1.2B | $715.5M |
| 总资产 | $2.0B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.61× | — |
8季度趋势，按日历期对齐
现金及短期投资LOARZLAB
| Q4 25 | $84.8M | $689.6M | ||
| Q3 25 | $99.0M | $717.2M | ||
| Q2 25 | $103.3M | $732.2M | ||
| Q1 25 | $80.5M | $757.3M | ||
| Q4 24 | $54.1M | $779.7M | ||
| Q3 24 | $55.2M | $616.1M | ||
| Q2 24 | $73.2M | $630.0M | ||
| Q1 24 | $28.2M | $650.8M |
总债务LOARZLAB
| Q4 25 | $715.7M | — | ||
| Q3 25 | $279.4M | — | ||
| Q2 25 | $277.7M | — | ||
| Q1 25 | $277.5M | — | ||
| Q4 24 | $277.3M | — | ||
| Q3 24 | $602.1M | — | ||
| Q2 24 | $250.7M | — | ||
| Q1 24 | $534.2M | — |
股东权益LOARZLAB
| Q4 25 | $1.2B | $715.5M | ||
| Q3 25 | $1.2B | $759.9M | ||
| Q2 25 | $1.1B | $791.7M | ||
| Q1 25 | $1.1B | $810.8M | ||
| Q4 24 | $1.1B | $840.9M | ||
| Q3 24 | $769.8M | $667.7M | ||
| Q2 24 | $758.4M | $704.2M | ||
| Q1 24 | $420.6M | $762.2M |
总资产LOARZLAB
| Q4 25 | $2.0B | $1.2B | ||
| Q3 25 | $1.5B | $1.2B | ||
| Q2 25 | $1.5B | $1.2B | ||
| Q1 25 | $1.5B | $1.2B | ||
| Q4 24 | $1.5B | $1.2B | ||
| Q3 24 | $1.5B | $985.3M | ||
| Q2 24 | $1.1B | $987.4M | ||
| Q1 24 | $1.1B | $988.4M |
负债/权益比LOARZLAB
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.24× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.78× | — | ||
| Q2 24 | 0.33× | — | ||
| Q1 24 | 1.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 2.43× | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流LOARZLAB
| Q4 25 | $30.4M | $-26.0M | ||
| Q3 25 | $29.7M | $-32.0M | ||
| Q2 25 | $23.8M | $-31.0M | ||
| Q1 25 | $28.4M | $-61.7M | ||
| Q4 24 | $20.7M | $-55.8M | ||
| Q3 24 | $16.3M | $-26.8M | ||
| Q2 24 | $7.1M | $-42.2M | ||
| Q1 24 | $10.8M | $-90.1M |
自由现金流LOARZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率LOARZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度LOARZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率LOARZLAB
| Q4 25 | 2.43× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.42× | — | ||
| Q1 25 | 1.85× | — | ||
| Q4 24 | 5.62× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 4.81× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
